Beryl Drugs Ltd
NSE: BSE: 524606
₹20.84
(4.99%)
Sun, 31 May 2026, 01:55 am
Market Cap105.69M
PE Ratio24.85
Dividend0
Health Technology
Pharmaceuticals: Other
24.5KBeryl Drugs Analysis
dividend
- Unable to evaluate Beryl Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Beryl Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Beryl Drugs is profitable, therefore cash runway is not a concern.
- Beryl Drugs is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (95.6%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.5x debt.
- Beryl Drugs's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 11.1x coverage).
- Beryl Drugs's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- The level of debt compared to net worth has increased over the past 5 years (25.7% vs 47% today).
- Beryl Drugs's level of debt (47%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- Sanjay's remuneration is lower than average for companies of similar size in India.
- Sanjay's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Beryl Drugs board of directors is less than 3 years, this suggests a new board.
misc
- Beryl Drugs is not covered by any analysts.
- Beryl Drugs has significant price volatility in the past 3 months.
past
- Beryl Drugs has delivered over 20% year on year earnings growth in the past 5 years.
- Beryl Drugs has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Beryl Drugs's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Beryl Drugs used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Beryl Drugs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Beryl Drugs's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Beryl Drugs's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Beryl Drugs's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Beryl Drugs is good value based on assets compared to the IN Pharmaceuticals industry average.
- Beryl Drugs is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Beryl Drugs is good value based on earnings compared to the India market.
- BSE:524606 is up 68.5% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524606 is up 68.5% outperforming the market in India which returned 8% over the past month.
- 524606 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524606 underperformed the Market in India which returned -14.5% over the past year.